Epiminder Presents at 2024 American Epilepsy Society Meeting
- Epiminder presents growing clinical evidence for Minder®, its world-first, bilateral, continuous EEG monitoring system
- Study data demonstrate Minder’s ability to generate a continuous, high-quality EEG signal to improve the treatment of epilepsy
Melbourne, Australia – December 9, 2024 – Medtech company Epiminder is presenting multiple posters and abstracts at the prestigious 2024 American Epilepsy Society Annual Meeting in Los Angeles from 6-10 December. Epiminder is developing and commercialising an implantable continuous electroencephalogram monitoring (iCEM) device called Minder to help treat epilepsy. Minder provides unprecedented, long-term, high-quality EEG data to provide both clinicians and patients with objective information to make clinical decisions.
Epiminder is presenting data demonstrating Minder is capable of continuous EEG monitoring in multiple subjects to help determine when and where seizures occur in the brain to better inform treatment options for patients with epilepsy. Minder is the only device providing such long-term, bilateral, detailed EEG data and has US FDA Breakthrough Device Designation. Data presented at the Annual Meeting shows patients tolerate the implantation and management of Minder well. Further, Epiminder is presenting evidence that its sub-scalp electrode detects electrographic activity as well as existing gold standard external EEG electrodes.
Rohan Hoare, Epiminder’s Chief Executive Officer, stated:
We are pleased to present our most recent clinical evidence to the researchers, industry, and health care professionals at this year’s American Epilepsy Society meeting. The data we are presenting demonstrates critical elements needed for a high-quality, continuous EEG monitoring system. We believe Minder will provide the personalised insights to transform the treatment of drug-resistant epilepsy.
We look forward to continuing to partner with leading epilepsy clinicians and patients to explore the transformational capability and clinical value of our implantable system and the objective, longitudinal data it generates. Our goal is to empower epilepsy patients to achieve seizure freedom.
About epilepsy
Epilepsy affects 80 million people globally with current medications only effective in two in three cases. It is the most common brain disorder worldwide and can affect people at any age. More than 250,000 Australians and 3.4 million Americans are currently living with epilepsy. Refractory epilepsy, which cannot be adequately managed through drug therapy, affects 30-40% of epilepsy patients.
About Minder
Minder is a minimally invasive device for continuous monitoring of electrographic activity of the brain, providing patients and their doctors with detailed data on brain activity over an extended period. Patients can wear the device as they go about their normal daily activities.
Minder’s long-term monitoring of patients outside of a controlled clinical environment provides data needed for better understanding and more effective treatment of underlying conditions, including determining the effectiveness of drug therapies and other potential interventions. Currently, Minder is available for investigational use only.
About Epiminder
Epiminder is a medical device company focused on the development of a sub-scalp, continuous EEG monitoring system for people who suffer from epilepsy and other seizure disorders where continuous monitoring is required. Epiminder is headquartered in Melbourne, Australia and has subsidiaries in the United States.